Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABL1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ABL1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ABL1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ABL1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457852 | Colorectum | MSS | positive regulation of cell adhesion | 110/3467 | 437/18723 | 2.94e-04 | 3.87e-03 | 110 |
GO:00015582 | Colorectum | MSS | regulation of cell growth | 105/3467 | 414/18723 | 2.97e-04 | 3.90e-03 | 105 |
GO:00719002 | Colorectum | MSS | regulation of protein serine/threonine kinase activity | 93/3467 | 359/18723 | 2.98e-04 | 3.91e-03 | 93 |
GO:00064692 | Colorectum | MSS | negative regulation of protein kinase activity | 60/3467 | 212/18723 | 3.08e-04 | 4.02e-03 | 60 |
GO:00901322 | Colorectum | MSS | epithelium migration | 93/3467 | 360/18723 | 3.30e-04 | 4.24e-03 | 93 |
GO:00106312 | Colorectum | MSS | epithelial cell migration | 92/3467 | 357/18723 | 3.87e-04 | 4.86e-03 | 92 |
GO:00467772 | Colorectum | MSS | protein autophosphorylation | 63/3467 | 227/18723 | 3.96e-04 | 4.91e-03 | 63 |
GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
GO:00425422 | Colorectum | MSS | response to hydrogen peroxide | 44/3467 | 146/18723 | 4.40e-04 | 5.30e-03 | 44 |
GO:00320921 | Colorectum | MSS | positive regulation of protein binding | 29/3467 | 85/18723 | 4.44e-04 | 5.32e-03 | 29 |
GO:19012142 | Colorectum | MSS | regulation of neuron death | 83/3467 | 319/18723 | 5.28e-04 | 5.99e-03 | 83 |
GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
GO:00106322 | Colorectum | MSS | regulation of epithelial cell migration | 77/3467 | 292/18723 | 5.39e-04 | 6.04e-03 | 77 |
GO:00901302 | Colorectum | MSS | tissue migration | 93/3467 | 365/18723 | 5.42e-04 | 6.06e-03 | 93 |
GO:00351481 | Colorectum | MSS | tube formation | 44/3467 | 148/18723 | 6.06e-04 | 6.68e-03 | 44 |
GO:01501162 | Colorectum | MSS | regulation of cell-substrate junction organization | 25/3467 | 71/18723 | 6.31e-04 | 6.94e-03 | 25 |
GO:00017631 | Colorectum | MSS | morphogenesis of a branching structure | 55/3467 | 196/18723 | 6.70e-04 | 7.25e-03 | 55 |
GO:00480412 | Colorectum | MSS | focal adhesion assembly | 29/3467 | 87/18723 | 6.84e-04 | 7.37e-03 | 29 |
GO:00106342 | Colorectum | MSS | positive regulation of epithelial cell migration | 50/3467 | 176/18723 | 8.50e-04 | 8.75e-03 | 50 |
GO:00018381 | Colorectum | MSS | embryonic epithelial tube formation | 37/3467 | 121/18723 | 8.95e-04 | 9.13e-03 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABL1 | SNV | Missense_Mutation | | c.1375N>C | p.Tyr459His | p.Y459H | P00519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1819N>C | p.Glu607Gln | p.E607Q | P00519 | protein_coding | deleterious_low_confidence(0.02) | benign(0.315) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | SNV | Missense_Mutation | rs780527035 | c.119N>G | p.Asn40Ser | p.N40S | P00519 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.97) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1503C>A | p.Asp501Glu | p.D501E | P00519 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ABL1 | SNV | Missense_Mutation | | c.268N>A | p.Asp90Asn | p.D90N | P00519 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ABL1 | SNV | Missense_Mutation | novel | c.1471A>T | p.Met491Leu | p.M491L | P00519 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Frame_Shift_Ins | novel | c.1125_1126insA | p.Asn377LysfsTer24 | p.N377Kfs*24 | P00519 | protein_coding | | | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | deletion | Frame_Shift_Del | | c.2409delC | p.Arg804GlyfsTer3 | p.R804Gfs*3 | P00519 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Nonsense_Mutation | novel | c.104_105insCCTGGCCTCGTTGTGGAGCGGCTCGTAATCCATCAT | p.Gly35_Gly36insLeuAlaSerLeuTrpSerGlySerTerSerIleMet | p.G35_G36insLASLWSGS*SIM | P00519 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL1 | deletion | Frame_Shift_Del | novel | c.3216_3225delNNNNNNNNNN | p.Ser1073TrpfsTer12 | p.S1073Wfs*12 | P00519 | protein_coding | | | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | DASATINIB | DASATINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | PAZOPANIB | PAZOPANIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | GENISTEIN | GENISTEIN | 9349317 |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | 249565818 | | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Nilotinib | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | vincristine | VINCRISTINE | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Asciminib | ASCIMINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | AZD0530 | SARACATINIB | |